BTIG raised the firm’s price target on MacroGenics to $24 from $12 and keeps a Buy rating on the shares. The firm is citing its recent conversations with key opinion leaders who “remain excited about vobra duo’s potential in prostate cancer”, the analyst tells investors in a research note. The interactions suggest that the data reported at ESMO 2021 showed remarkable efficacy, and comparable data from the upcoming trial would be “exciting”, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MGNX:
- MacroGenics to Participate in Upcoming Investor Conferences
- MacroGenics price target raised to $23 from $12 at Barclays
- MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
- MGNX Upcoming Earnings Report: What to Expect?
- MacroGenics downgraded to Neutral from Buy at H.C. Wainwright
